Viridian Therapeutics (VRDN) 10-Q2020 Q3 Quarterly report

Filed: 12 Nov 20, 7:04am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: abbreviated, antibody, Assent, batch, BLA, BPCIA, Brexit, bulging, buy, Canadian, catalyze, China, Commissioner, concept, constitute, consummate, consummation, CUSIP, CVR, Deadline, debilitating, deceptive, destruction, dissolution, double, endeavor, fractional, freely, gathered, HHS, Horizon, ImmunoGen, Immunovant, improper, installation, instrument, insulin, interchangeable, issuable, Jonathan, Justice, lawfully, Lee, legacy, lockup, logistical, meant, MGEN, microbial, misrepresentative, monoclonal, nonessential, nurse, oncology, parallel, pathway, pharmacokinetic, proof, proportion, Rauch, reagent, reclassified, requisite, Royal, rulemaking, substituted, substitution, surgical, swap, symbol, TED, therewith, thyroid, ticker, tie, UK, underserved, unfair, unfold, variation, vendor, Violin, viral, Viridian, VStock

Removed: abnormally, ACA, addressable, adjust, adult, AG, allotted, Alnylam, amenable, aminotransferase, approach, Argenx, Arrowhead, ascribed, aspartate, ATLL, attribute, biology, blocking, blood, body, Boehringer, Celgene, chemical, chemistry, closure, collaborated, conclusion, confirmation, considerable, Copenhagen, creatine, CTCL, delivering, diarrhea, Dicerna, discovering, diseased, dosing, edema, efficiently, erythema, erythroderma, exfoliative, extensively, familiar, fatigue, feasibility, fibrotic, finalization, frame, gene, GmbH, Hakko, halted, headache, healing, heart, Helsinn, highest, incidence, incorrect, Ingelheim, inhibitor, innate, interact, InteRNA, intradermal, intralesional, kidney, kinase, Kirin, Kyowa, length, Likewise, literature, localized, lung, malignant, marketable, Marshall, medicine, Merck, MF, mild, moderate, Mylan, nausea, neutropenia, offered, oligonucleotide, opposed, pain, pathological, people, perspective, Pharma, pharmacological, predominantly, prescribing, Presently, proven, quickly, range, regulate, RICC, Roche, role, Seattle, Silence, skin, solved, solving, Spectrum, Squibb, stabilizing, stricter, subset, systemic, Takeda, targeting, thought, toxicity, translational, unexpected, unproven, unsafe, unusually, utilizing, Valeant, validated, validation, William, worse

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

VRDN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

SECTION 1350 CERTIFICATION

Each of the undersigned, Lee Rauch, Chief Executive Officer of Miragen Therapeutics, Inc., a Delaware corporation (the “Company”), and Jason A. Leverone, Chief Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his or her knowledge (1) the Quarterly Report on Form 10-Q of the Company for the quarterly period ended September 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


									/s/ Lee Rauch
									Lee Rauch
									Chief Executive Officer
									(Principal Executive Officer)
									Date: November 12, 2020

									/s/ Jason A. Leverone
									Jason A. Leverone
									Chief Financial Officer
									(Principal Financial Officer; Principal Accounting Officer)
									Date: November 12, 2020

This certification accompanies and is being “furnished” with this Report, shall not be deemed “filed” by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Report, irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.